On July 19, 2025, in Hanoi, the VNUHCM-US Stem Cell Institute (SCI) and Hòa Lạc Stem Cell Technology Joint Stock Company (Hòa Lạc Stem Cell – HSC) officially signed a Memorandum of Understanding (MoU), marking an important step forward in scientific and technological cooperation between the two parties.Vision for Collaboration

The two sides commit to establishing a sustainable, strategic partnership aimed at:

• Enhancing community health care quality through high-tech medical services.
• Promoting regenerative medicine by applying stem cells and immune cells in clinical treatment.
• Standardizing procedures according to international standards (ISCT, AABB, FACT) and Vietnamese law.

Key Areas of Collaboration
Under the agreement, the two parties will focus on five domains:

1. Advanced Training: SCI will transfer technologies for stem cell / immune cell isolation, culture, and preservation to the HSC staff.
2. Technical Transfer: Deploy advanced, internationally-compliant processes from collection to clinical application.
3. Quality Monitoring: Establish internal control systems aiming for international certification.
4. Joint Research: Collaborate on scientific projects and expand treatment scopes.
5. Parallel Communication: Raise public awareness of regenerative medicine.

Participating in the signing ceremony, the SCI was represented by Assoc. Prof. Pham Van Phuc (Director); and HSC by Mr. Phan Tú Quân (CEO).

During the event, Assoc. Prof. Pham Van Phuc delivered a presentation on “Stem Cell Economics & Business,” providing attendees with an overview of current economic and business trends in the stem cell industry.